The closing price of Ocuphire Pharma Inc (NASDAQ: OCUP) was $1.99 for the day, down -16.39% from the previous closing price of $2.38. In other words, the price has decreased by -$0.3900 from its previous closing price. On the day, 815914 shares were traded. OCUP stock price reached its highest trading level at $2.3500 during the session, while it also had its lowest trading level at $1.9300.
Ratios:
Our analysis of OCUP’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.95 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 2.07. For the most recent quarter (mrq), Quick Ratio is recorded 13.86 and its Current Ratio is at 13.35. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUP now has a Market Capitalization of 47.88M and an Enterprise Value of 28.71M. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.51 while its Price-to-Book (P/B) ratio in mrq is 0.96. Its current Enterprise Value per Revenue stands at 0.50 whereas that against EBITDA is 0.99.
Stock Price History:
Over the past 52 weeks, OCUP has reached a high of $6.60, while it has fallen to a 52-week low of $2.34. The 50-Day Moving Average of the stock is 2.7162, while the 200-Day Moving Average is calculated to be 3.3567.
Shares Statistics:
OCUP traded an average of 201.79K shares per day over the past three months and 224.28k shares per day over the past ten days. A total of 23.98M shares are outstanding, with a floating share count of 22.23M. Insiders hold about 7.59% of the company’s shares, while institutions hold 15.43% stake in the company. Shares short for OCUP as of Feb 15, 2024 were 1.75M with a Short Ratio of 8.66, compared to 1.66M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 7.26% and a Short% of Float of 7.48%.
Earnings Estimates
The firm’s stock currently is rated by 4 analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of $0.32 and a low estimate of -$0.26, while EPS last year was $1.58. The consensus estimate for the next quarter is -$0.1, with high estimates of $0 and low estimates of -$0.23.
Analysts are recommending an EPS of between $0.09 and -$0.52 for the fiscal current year, implying an average EPS of -$0.3. EPS for the following year is -$0.23, with 4 analysts recommending between $1.12 and -$0.9.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 4 analysts. It ranges from a high estimate of $13.13M to a low estimate of $1.8M. As of the current estimate, Ocuphire Pharma Inc’s year-ago sales were $39.85M, an estimated decrease of -86.60% from the year-ago figure. For the next quarter, 2 analysts are estimating revenue of $5.2M, an increase of 197.30% over than the figure of -$86.60% in the same quarter last year. There is a high estimate of $7.4M for the next quarter, whereas the lowest estimate is $3M.
A total of 4 analysts have provided revenue estimates for OCUP’s current fiscal year. The highest revenue estimate was $30.48M, while the lowest revenue estimate was $19.1M, resulting in an average revenue estimate of $22.7M. In the same quarter a year ago, actual revenue was $39.85M, down -43.00% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $28.53M in the next fiscal year. The high estimate is $52.48M and the low estimate is $13.46M. The average revenue growth estimate for next year is up 25.70% from the average revenue estimate for this year.
